Propofol

Generic Name: Propofol

Brand Names: Diprivan

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₈O

CAS Number: 2078-54-8

Unique Ingredient Identifier: YI7VU623SF

Background: Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.

Indication: Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.

Associated Therapies: Induction of anesthesia therapy, Maintenance of anesthesia therapy, Monitored anesthesia care sedation, Sedative therapy

Clinical Trials

FDA Approves Avenacy's Propofol Injectable Emulsion as Generic Alternative to Diprivan

a month ago

• Avenacy has launched FDA-approved Propofol Injectable Emulsion, USP in the United States as a therapeutic generic equivalent to Diprivan for intravenous general anesthesia and sedation. • The medication is indicated for multiple uses including induction and maintenance of general anesthesia, monitored anesthesia care sedation, and intensive care unit sedation of intubated patients. • Available in three dosage formats with specialized packaging for medication safety, the product represents Avenacy's 21st launch since October 2023 in a market worth approximately $315 million annually.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy